FMTX
NASDAQForma Therapeutics Holdings Inc.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Forma Therapeutics Holdings Inc. (Amendment)SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
- SECSEC Form 15-12G filed by Forma Therapeutics Holdings Inc.15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form EFFECT filed by Forma Therapeutics Holdings Inc.EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- INSIDERSEC Form 4: Lesser Brian Andrew closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Potts Jeannette closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Frederick Wayne A.I. closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Lee Frank D. closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Fanucci Marsha closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Bishop John E closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Melian Agustin closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Molina Arturo Md closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Clackson Timothy P closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Shegog Todd closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Wirth Peter closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- INSIDERSEC Form 4: Wiggans Thomas G closing all direct ownership in the company4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Forma Therapeutics Holdings Inc. (Amendment)SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)
- SECSEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form POS AM filed by Forma Therapeutics Holdings Inc.POS AM - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)
- SECSEC Form SC 14D9/A filed by Forma Therapeutics Holdings Inc. (Amendment)SC 14D9/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
- SECSEC Form SC TO-T/A filed by Forma Therapeutics Holdings Inc. (Amendment)SC TO-T/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
- SECSEC Form 25-NSE filed by Forma Therapeutics Holdings Inc.25-NSE - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)
FMTX FAQ
7 questionsWhat does Forma Therapeutics Holdings Inc. do?
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for...Where does FMTX stock trade?
Forma Therapeutics Holdings Inc. (FMTX) is listed on NASDAQ.What sector and industry is FMTX in?
Forma Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Forma Therapeutics Holdings Inc. go public?
Forma Therapeutics Holdings Inc. (FMTX) completed its IPO in 2020.What are analysts saying about FMTX?
Forma Therapeutics Holdings Inc. has had 4 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $2100.00 price target on 2022-06-13. Recent price targets range from $2100.00 to $4000.00.What companies are similar to FMTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FMTX side-by-side with any of them on Quantisnow.How can I track FMTX on Quantisnow?
Quantisnow aggregates Forma Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FMTX to receive live email and push alerts on every new disclosure.